SUPN News and Press, Supernus Pharmaceuticals Inc. From 11/03/21

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2021 Earnings Conference Call November 03, 2021 04:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Steinberg - Jefferi...

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) are up ~10% in after-hours trading after the company boosted its full-year earnings guidance and beat Q3 earnings estimates. Operating earnings for 2021 are now expected to be $90M-$95M, up from prior guidance of $70M-$90M. Net produc...

Supernus Pharmaceuticals (NASDAQ:SUPN): Q3 GAAP EPS of $0.40 beats by $0.17. Revenue of $148.5M (-4.3% Y/Y) beats by $6.38M. Press Release Full Year 2021 Financial Guidance: Total revenues of $550M - $570M (prior $550M - $580M) vs. consensus of $560.68M; Operating earnings of $...

Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020 Third quarter 2021 total revenues were $148.5 million, a 4% decrease compared to $155.1 million in third quarter 2020 Strengthen Parki...

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fina...

Adamas Pharmaceuticals announced that Supernus Pharmaceuticals has struck a deal to buy ADMS at $8.10 per share with CVR kickers. I believe this is a perfect time for both companies. Supernus' leading product, Trokendi, is moving closer to its patent expiration in 2023. GOCOVRI might ...

Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...

Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversity Nearly one-in-ten – or 6.1 million children and adolescents – are affected by ADHD ROCKVILLE, Md., Oct. 2...

Potential deal in the works Aspen Technology materializes. Two deals with Contingent Value Rights announced last week. Navios Maritime Partners completed the acquisition of Navios Maritime Acquisition Corporation. For further details see: Merger Arbitrage Mondays: Emerso...

Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...